Since 1971, the landscape of drug research in the United States has been drastically altered, with severe restrictions placed on the study of substances deemed “most dangerous.” The Controlled Substances Act (CSA), ostensibly implemented for public protection, has instead created a system that inadvertently benefits pharmaceutical companies by maintaining their monopoly on drug manufacturing and distribution.
A new collaboration brings together iconic functional glass, carefully selected cannabis genetics and a mission…
This interview by Micah Johnson originally appeared in High Times Local, produced under license by…
Congress's watchdog confirmed the DEA has no complete written procedures for drug scheduling. Learn why…
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…